BREnnA: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Condition: Breast Cancer

Sponsor: Hoffmann-La Roche

Full Title
Protocol WO46069: A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

Study Treatment
HER2 targeting TKI RO7771950 + Trastuzumab + Capecitabine vs Tucatinib + Trastuzumab + Capecitabine

Eligibility/Info
Eligible participants must have HER2+ advanced or metastatic HER2+ breast cancer. Must have previously been treated with at least 1 line of therapy including at least one HER2 targeting antibody-drug conjugate but no prior treatment with a HER2 targeting TKI. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage